Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT

NCT04844866 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT04844866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04844866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
August 18, 2021
Completion date
September 30, 2031
Enrollment
213 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma